temozolomide has been researched along with regorafenib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Desideri, I; Detti, B; Ganovelli, M; Greto, D; Livi, L; Lorenzetti, V; Lucidi, S; Maragna, V; Scoccianti, S; Scoccimarro, E; Teriaca, MA | 1 |
| Ali, AAA; Chiang, IT; Chou, SY; Hsu, FT; Hsu, TI; Liu, HS; Liu, YC | 1 |
| Ding, N; Huang, C; Jia, W; Jiang, J; Li, L; Luo, M; Nice, EC; Tian, H; Zhang, H; Zhou, L | 1 |
3 other study(ies) available for temozolomide and regorafenib
| Article | Year |
|---|---|
Regorafenib in glioblastoma recurrence: A case report.
Topics: Brain Neoplasms; Chemoradiotherapy, Adjuvant; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Temozolomide; Treatment Outcome | 2021 |
Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Glioblastoma; Humans; NF-kappa B; Phenylurea Compounds; Pyridines; Receptors, CXCR4; Temozolomide | 2022 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; Humans; Temozolomide | 2023 |